The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

December 31, 2013

Conditions
Diabetes Mellitus, Type 2Medication AdherenceHYPERGLYCEMIA
Interventions
OTHER

Diabetes medication management

As above plus- Follow-up intervention visits were at 24-72 hrs, 2 and 4 weeks. During each, further DSME was provided, BG logs reviewed, and diabetes medications adjusted as needed by the CDE. Meter and insulin injections skills were reinforced as needed. Outpatient navigation included securing a primary care appointment no later than 4 weeks after study completion. Final contact was via telephone at 90 days. The MMS© (Morisky Medication Adherence Survey) was taken at 2 and 4 weeks and during the final telephone visit. Interim return visits to the ED or admissions to the hospital were queried at each visit. A follow up HbA1C was obtained at week 4 using the POC A1CNow+ ®, and a venous HbA1C was drawn if the POC result was above 13% .

Trial Locations (1)

20010

MedStar Washington Hospital Center, Washington D.C.

Sponsors
All Listed Sponsors
collaborator

American Diabetes Association

OTHER

collaborator

Sanofi

INDUSTRY

collaborator

Bayer

INDUSTRY

lead

Medstar Health Research Institute

OTHER